125 related articles for article (PubMed ID: 23892816)
1. Survey of carboplatin dosing strategies in oncology practices.
Blankenship P; Waddell JA
J Am Pharm Assoc (2003); 2013; 53(4):420-2. PubMed ID: 23892816
[TBL] [Abstract][Full Text] [Related]
2. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia.
Herrington JD; Tran HT; Riggs MW
Cancer Chemother Pharmacol; 2006 Jan; 57(2):241-7. PubMed ID: 16133538
[TBL] [Abstract][Full Text] [Related]
4. Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors.
Kaag D
Lung Cancer; 2013 Jan; 79(1):54-8. PubMed ID: 23131495
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
Ekhart C; Rodenhuis S; Schellens JH; Beijnen JH; Huitema AD
Cancer Chemother Pharmacol; 2009 Jun; 64(1):115-22. PubMed ID: 18989671
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin dosing for adult Japanese patients.
Ando Y; Shimokata T; Yasuda Y; Hasegawa Y
Nagoya J Med Sci; 2014 Feb; 76(1-2):1-9. PubMed ID: 25129986
[TBL] [Abstract][Full Text] [Related]
7. Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review.
Morrow A; Garland C; Yang F; De Luna M; Herrington JD
J Oncol Pharm Pract; 2019 Oct; 25(7):1651-1657. PubMed ID: 30336729
[TBL] [Abstract][Full Text] [Related]
8. Flat dosing of carboplatin is justified in adult patients with normal renal function.
Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
[TBL] [Abstract][Full Text] [Related]
9. Variability of carboplatin dose calculation methods in Spain.
Cuesta-Grueso C; Burgos-San José A; Cajaraville-Ordoñana G; Poquet-Jornet JE; Mangues-Bafalluy I; Díaz-Carrasco MS
J Oncol Pharm Pract; 2019 Oct; 25(7):1551-1557. PubMed ID: 30176785
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies.
de Lemos ML; Hsieh T; Hamata L; Levin A; Swenerton K; Djurdjev O; Vu T; Hu F; Conklin J; Malfair Taylor SC
Gynecol Oncol; 2006 Dec; 103(3):1063-9. PubMed ID: 16875719
[TBL] [Abstract][Full Text] [Related]
11. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula.
Nagao S; Fujiwara K; Imafuku N; Kagawa R; Kozuka Y; Oda T; Maehata K; Ishikawa H; Koike H; Aotani E; Kohno I
Gynecol Oncol; 2005 Nov; 99(2):327-33. PubMed ID: 16005943
[TBL] [Abstract][Full Text] [Related]
12. Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma.
Shepherd ST; Gillen G; Morrison P; Forte C; Macpherson IR; White JD; Mark PB
Eur J Cancer; 2014 Mar; 50(5):944-52. PubMed ID: 24445148
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin dosing based on measurement of renal function--experience at the Peter MacCallum Cancer Institute.
Millward MJ; Webster LK; Toner GC; Bishop JF; Rischin D; Stokes KH; Johnston VK; Hicks R
Aust N Z J Med; 1996 Jun; 26(3):372-9. PubMed ID: 8811211
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.
Duong JK; Veal GJ; Nath CE; Shaw PJ; Errington J; Ladenstein R; Boddy AV
Br J Clin Pharmacol; 2019 Jan; 85(1):136-146. PubMed ID: 30261554
[TBL] [Abstract][Full Text] [Related]
15. Extension of the Calvert formula to patients with severe renal insufficiency.
Oguri T; Shimokata T; Ito I; Yasuda Y; Sassa N; Nishiyama M; Hamada A; Hasegawa Y; Ando Y
Cancer Chemother Pharmacol; 2015 Jul; 76(1):53-9. PubMed ID: 25957958
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate.
Dooley MJ; Poole SG; Rischin D; Webster LK
Eur J Cancer; 2002 Jan; 38(1):44-51. PubMed ID: 11750838
[TBL] [Abstract][Full Text] [Related]
17. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level.
Ando M; Minami H; Ando Y; Saka H; Sakai S; Yamamoto M; Sasaki Y; Shimokata K; Hasegawa Y
Clin Cancer Res; 2000 Dec; 6(12):4733-8. PubMed ID: 11156227
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin.
van Warmerdam LJ; Rodenhuis S; ten Bokkel Huinink WW; Maes RA; Beijnen JH
Cancer Chemother Pharmacol; 1996; 37(3):266-70. PubMed ID: 8529288
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetics and individual dose adjustment of carboplatin].
Chatelut E; Canal P; Bugat R
Bull Cancer; 2000 Aug; 87 Spec No():17-23. PubMed ID: 11082718
[TBL] [Abstract][Full Text] [Related]
20. Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing.
Ando Y; Minami H; Saka H; Ando M; Sakai S; Shimokata K
Br J Cancer; 1997; 76(8):1067-71. PubMed ID: 9376268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
